HotHouse Therapeutics, based in Norwich, Norfolk, has developed an AI-driven plant bioengineering system capable of designing and growing new chemistry within days. The platform combines pathway-prediction algorithms with the vast enzymatic diversity of the plant kingdom and can currently generate over 20 million novel molecules. Its vertical-farm-ready production process is carbon positive, offering a sustainable and affordable alternative to extractive or resource-heavy chemical synthesis. The company’s initial commercial focus is on producing next-generation vaccine adjuvants, but management also plans to launch traditional drug-discovery programs and progress selected assets into clinical development. By coupling rapid molecule generation with scalable cultivation, the company aims to shorten R&D timelines and lower production costs for biologically active compounds. The recent funding marks the company’s first institutional capital, positioning it to expand operations and intensify R&D efforts around its discovery pipeline.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2025